IRCT20200701047979N1 IRCT 2020-07-20 Tehran University of Medical Sciences Effect of Levetiracetam on Benzodiazepine Withdrawal Syndrome Evaluating the Effect of Levetiracetam on Benzodiazepine Withdrawal Syndrome in Comparison with Placebo 2020-06-28 anticipated 39 Complete https://irct.ir/trial/49453 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Sampling takes place when a patient is referred to the emergency room of Roozbeh hospital, and he/she meets the study’s inclusion and exclusion criteria. For sampling allocation, permuted block randomization technic was used to prepare a randomizing table, Blinding description: Patients participating in the study. 3 Benzodiazepine Withdrawal Syndrome. Intervention 1: Control group: patients in this group are given placebo 2 times a day for 2 weeks-The placebos are the exact physical replica of Levetiracetam tablets manufactured by Abidi Pharmaceutics. All the excipients are chemically the same and only the API (Active Pharmaceutical Ingredient) is removed. Intervention 2: Intervention group: patients in this group are given 500 milligrams of Levetiracetam 2 times a day for 2 weeks.-Both Levetiracetam tablets and the placebos are manufactured by Abidi Pharmaceutics. No - There is not a plan to make this available Justification or reason for not sharing IPD is There is no further information